Trypanosoma cruzi, the protozoan parasite that causes Chagas' disease in humans, has a complex life cycle alternating between the insect vector and the mammalian host. In the vector, it multiplies as noninfective epimastigotes that migrate to the hindgut and differentiate into infective metacyclic trypomastigotes. During the insect blood meal, the metacyclic trypomastigotes are deposited with the feces and urine near a skin wound, initiating the natural infection.T. cruzi is unable to synthesize sialic acids (SA), 1 but it expresses a unique trans-sialidase (TS), which transfers ␣2-3-linked SA from host glycoproteins and glycolipids to acceptors containing terminal -galactosyl residues present on the parasite surface (reviewed in Refs. 1-4). Several studies characterizing the nature and structure of the SA acceptors have been published. These acceptors are abundant on the parasite surface and were first described as major surface glycoproteins of epimastigotes by Alves and Colli (5), who called them bands A, B, and C. Subsequently, a similar cell surface glycoprotein complex, called GP24, GP31, and GP37 was described by Ferguson et al. (6), and Previato et al. (7) first described a 43-kDa SA acceptor. More recently, they have been called 38/43 glycoconjugates (8), and the so called epimastigote lipophosphoglycan-like molecule could belong to the same family of molecules (9). In metacyclic trypomastigote forms, the SA acceptors were reported originally as the 35/50-kDa antigens (10, 11) that were subsequently defined as mucin-like glycoproteins (12). In the trypomastigote forms found in mammals, the SA acceptors were described as a group of molecules that share the stagespecific epitope 3 (Ssp-3) (13), an epitope dependent on parasite